Company & Sponsor Intelligence

Axsome Therapeutics, Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting1

Completed1

Countries1

Therapeutic footprint

adhdalzheimers

Indexed studies

NCT04947553A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
alzheimers · United StatesPHASE3

NCT07717879Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
adhd · United StatesPHASE3

NCT06736509An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
alzheimers · United StatesPHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →